From the first clinic visit to the second, therewas an increase in angiotensin-converting enzyme inhibitor/angiotensinreceptor blocker (ACE-I/ARB) use across all disease groups—from 33% to 46%(P = .028) in patients with diabetes, from 30% to 57%(P = .002) in patients with CAD, and from 16% to 35%(P < .001) in patients with preexisting CKD. The gene discussed is ACE; the disease is coronary artery disorder.